Your browser version is outdated. We recommend that you update your browser to the latest version.

SteveSteve

 

 

 

 

 

 

 

 

 

EDUCATION

 

University of Toronto, Faculty of Medicine 1993 - 1998

Ph.D. in Biochemistry

 

University of Toronto, Faculty of Arts and Science 1989 - 1993

B.Sc. Biochemistry Specialist with honours 

 


RESEARCH

 

University Health Network 2003 - 2016

Research Associate Level II

  • Managed medical biochemistry research lab
  • Managed X-ray diffraction facilities
  • Trained postdocs, graduate, and undergraduate students
  • Designed protein expression vectors for recombinant protein production
  • Purified and analyzed recombinant proteins
  • Performed a variety of enzyme and immunological assays
  • Crystallized Fab antibody fragments and ligand-complexed enzymes
  • Determined protein structures by X-ray diffraction techniques

 

GlycoDesign Inc. 2000 - 2003

Research Scientist

  • Conducted advanced enzyme kinetics experiments on selected drug targets
  • Successfully completed an HTS screen of a 70000-compound library
  • Redesigned the HTS assay protocol to reduce the cost by half
  • Introduced a variety of alternative enzyme assays
  • Purified and crystallized drug target enzymes
  • Organized and chaired a committee for SAR analysis

 

Apotex Research Inc. 1998 - 2000

Research Scientist

  • Developed novel enzyme assays to detect cysteine protease activity
  • Designed biochemical assays for a transglutaminase enzyme
  • Determined crystal structures of cysteine protease/inhibitor complexes
  • Detailed kinetic evaluation of irreversible inhibitor compounds

 


PUBLICATIONS

 

The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities (2018) MAbs doi: 10.1080/19420862.2018.1494107 (Epub ahead of print). U Dhagat, TR Hercus, SE Broughton, TL Nero, KS Cheung Tung Shing, EF Barry, CA Thomson, S Bryson, EF Pai, BJ McClure, JW Schrader, AF Lopez, MW Parker

 

Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma (2018) ChemMedChem13(9): 957-967. R De Gasparo, E Brodbeck-Persch, S Bryson, NB Hentzen, M Kaiser, EF Pai, RL Krauth-Siegel, F Diederich

 

Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop Variation (2016) J Immunol. 196: 4723-30. S Bryson, CA Thomson, LF Risnes, S Dasgupta, K Smith, JW Schrader, EF Pai

 

Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity (2016) J Med Chem. 59: 624-46. JD Goodreid, J Janetzko, JP Jr Santa Maria, KS Wong, E Leung, BT Eger, S Bryson, EF Pai, SD Gray-Owen, S Walker, WA Houry, RA Batey

 

Binding to Large Enzyme Pockets: Small-Molecule Inhibitors of Trypanothione Reductase (2014) ChemMedChem. 9(8): 1880-91. E Persch, S Bryson, NK Todoroff, C Eberle, J Thelemann, N Dirdjaja, M Kaiser, M Weber, H Derbani, R Brun, G Schneider, EF Pai, RL Krauth-Siegel, F Diederich

 

Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design (2014) J Biol Chem. 289: 6565-80. S Serrano, A Araujo, B Apellániz, S Bryson, P Carravilla, I de la Arada, N Huarte, E Rujas, EF Pai, JL Arrondo, C Domene, MA Jiménez, JL Nieva

 

Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope (2012) J Mol Biol. 41: 175-92. ML Azoitei, YE Ban, JP Julien, S Bryson, A Schroeter, O Kalyuzhniy, JR Porter, Y Adachi, D Baker, EF Pai, WR Schief

 

Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications (2009) J Virol. 83: 11862-75. S Bryson, JP Julien, RC Hynes, EF Pai

 

Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site (2008) J Mol Biol. 384: 377-92. JP Julien, S Bryson, JL Nieva, EF Pai

 

Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus (2008) EMBO J. 27: 2592-602. CA Thomson, S Bryson, GR McLean, AL Creagh, EF Pai, JW Schrader

 

Crystal structure of the complex between the F(ab) fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6 (2008) J Mol Biol. 382: 910-9. S Bryson, JP Julien, DE Isenman, R Kunert, H Katinger, EF Pai

 

A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity (2005) Mol Immunol. 42: 1111-9. GR McLean, M Torres, B Trotter, M Noseda, S Bryson, EF Pai, JW Schrader, A Casadevall

 

Highly conserved cysteines of mouse core 2 beta1,6-N-acetylglucosaminyltransferase I form a network of disulfide bonds and include a thiol that affects enzyme activity (2003) J Biol Chem. 278: 45864-81. TY Yen, BA Macher, S Bryson, X Chang, I Tvaroska, R Tse, S Takeshita, AM Lew, A Datti 

PATENT

Thiadiazole Compounds Useful as Inhibitors of Cysteine Activity Dependent Enzymes (2001) WO0190095. K Karimian, TF Tam, R Leung-Toung, W Li, S Bryson, and JM Wodzinska